Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus), By Region, And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1 Executive Summary
1.1 Market Summary
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Model
2.3.1 Historic And Base Year Estimates
2.3.2 Forecast Analysis
2.3.3 Study Of Approved Therapies By Disease Incidence
2.3.4 Study Of Approved Therapies By Vector
2.3.5 Region-Wise Approval
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Trends & Outlook
3.2 Market Segmentation
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Robust Gene Therapy Pipeline
3.3.1.2 Introduction Of Technological Advancements
3.3.1.3 Increasing Investment From Companies And Partnerships
3.3.1.4 Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
3.3.2 Market Restraint Analysis
3.3.2.1 Absence Of Effective Diagnosis Framework
3.3.2.2 High Prices Of Gene Therapy
3.3.3 Market Opportunity Analysis
3.3.3.1 Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
3.3.3.2 Facility Expansion For Cell And Gene Therapies
3.3.3.3 Technological Advancements In Manufacturing Vectors
3.3.4 Challenge Analysis
3.3.4.1 Production capacity challenges
3.3.4.2 Manufacturing challenges about large-scale production of vectors
3.4 Regulatory Framework
3.5 Major Deals & Strategic Alliances Analysis
3.5.1 Mergers & Acquisitions
3.5.2 Collaborations & Partnerships
3.6 Pipeline Analysis
3.7 Payment & Pricing Models
3.7.1 Payment Models For Innovative Therapies
3.8 Swot Analysis, by factor (Political & legal, economic, and technological)
3.9 Porter’s Five Forces Analysis
3.10 Number of Gene Therapy Doses Sold in 2022
3.11 Number of Patients Treated with Gene Therapy, 2022
Chapter 4 COVID-19 Impact Analysis
4.1 Key Market Initiatives
4.2 Conclusion
Chapter 5 Indication BusinessAnalysis
5.1 Gene Therapy Market: Indication Movement Analysis
5.2 Acute Lymphoblastic Leukemia (ALL)
5.2.1 Global Gene Therapy Market For Acute Lymphoblastic Leukemia (All), 2018 - 2030 (USD Million)
5.2.2 Global Acute Lymphoblastic Leukemia (All) Patients Treated With Gene Therapy, 2018 - 2030
5.3 Inherited Retinal Disease
5.3.1 Global Gene Therapy Market For Inherited Retinal Disease, 2018 - 2030 (USD Million)
5.3.2 Global Inherited Retinal Disease Patients Treated With Gene Therapy, 2018 - 2030
5.4 Large B-Cell Lymphoma
5.4.1 Global Gene Therapy Market For Large B-Cell Lymphoma, 2018 - 2030 (USD Million)
5.4.2 Global Large B-Cell Lymphoma Patients Treated With Gene Therapy, 2018 - 2030
5.5 Adenosine Deaminase (Ada)‐Deficient Severe Combined Immunodeficiency (Scid)
5.5.1 Global Gene Therapy Market For Ada-Scid, 2018 - 2030 (USD Million)
5.5.2 Global Ada-Scid Patients Treated With Gene Therapy, 2018 - 2030
5.6 Melanoma (Lesions)
5.6.1 Global Gene Therapy Market For Melanoma (Lesions), 2018 - 2030 (USD Million)
5.6.2 Global Melanoma (Lesions) Patients Treated With Gene Therapy, 2018 - 2030
5.7 Beta-Thalassemia Major/Sickle Cell Disease (Scd)
5.7.1 Global Gene Therapy Market For Beta Thalassemia Major/Sickle Cell Diseases, 2018 - 2030 (USD Million)
5.7.2 Global Beta Thalassemia Major/Sickle Cell Diseases Patients Treated With Gene Therapy, 2018 - 2030
5.8 Head & Neck Squamous Cell Carcinoma
5.8.1 Global Gene Therapy Market For Head & Neck Squamous Cell Carcinoma, 2018 - 2030 (USD Million)
5.8.2 Global Head & Neck Squamous Cell Carcinoma Patients Treated With Gene Therapy, 2018 - 2030
5.9 Peripheral Arterial Disease
5.9.1 Global Gene Therapy Market For Peripheral Arterial Disease, 2018 - 2030 (USD Million)
5.9.2 Global Peripheral Arterial Disease Patients Treated With Gene Therapy, 2018 - 2030
5.10 Spinal Muscular Atrophy (Sma)
5.10.1 Global Gene Therapy Market For Spinal Muscular Atrophy (Sma), 2018 - 2030 (USD Million)
5.10.2 Global Spinal Muscular Atrophy (Sma) Patients Treated With Gene Therapy, 2018 - 2030
5.11 Others
Chapter 6 Vector Type Business Analysis
6.1 Gene Therapy Market: Vector Type Movement Analysis
6.2 Gene Therapy Market: Vector Movement Analysis
6.3 Lentiviral Vectors
6.3.1 Global Lentivirus-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.4 Adeno-Associated Viral (Aav) Vectors
6.4.1 Global Aav-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.5 Retrovirus Vectors
6.5.1 Global Retrovirus Vectors-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.6 Modified Herpes Simplex Virus
6.6.1 Global Modified Herpes Simplex Virus Vectors -Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.7 Adenovirus Vectors
6.7.1 Global Adenovirus Vectors-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.8 Non-Viral Plasmid Vector
6.8.1 Global Non-Viral Plasmid Vector-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.9 Others
6.9.1 Global Others-Based Gene Therapy Market, 2018 - 2030 (USD Million)
Chapter 7 Regional Business Analysis
7.1 North America
7.1.1 SWOT ANALYSIS
7.1.1.1北美Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.3 Canada
7.1.3.1关键国家动力学
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2 EUROPE
7.2.1 SWOT Analysis:
7.2.1.1 Europe Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3 UK
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 UK Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3 Asia Pacific
7.3.1 SWOT ANALYSIS:
7.3.1.1 Key Region Dynamics
7.3.1.2 Asia Pacific Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2 Japan
7.3.2.1 Target Disease Prevalence
7.3.2.2 Competitive Scenario
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.2.5 Japan Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3 China
7.3.3.1 Target Disease Prevalence
7.3.3.2 Competitive Scenario
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.3.5 China Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4 India
7.3.4.1 Target Disease Prevalence
7.3.4.2 Competitive Scenario
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.4.5 India Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5 Austrlia
7.3.5.1 Target Disease Prevalence
7.3.5.2 Competitive Scenario
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.5.5 Austrlia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6 Rest Of Asia Pacific Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4 Rest of the World
7.4.1世界市场大霸王基因疗法tes and Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Company Profiles
8.1 Company Profiles
8.1.1 REGENXBIO, INC.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic Initiatives
8.1.2 OXFORD BIOMEDICA PLC
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic Initiatives
8.1.3 VOYAGER THERAPEUTICS
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic Initiatives
8.1.4 HUMAN STEM CELLS INSTITUTE
8.1.4.1 Company overview
8.1.4.2 Product benchmarking
8.1.4.3 Strategic Initiatives
8.1.5 DIMENSION THERAPEUTICS, INC.
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic Initiatives
8.1.6 BRISTOL-MYERS SQUIBB COMPANY
8.1.6.1 Company overview
8.1.6.1.1 Celgene Corporation
8.1.6.2 Financial performance (Bristol-Myers Squibb)
8.1.6.2.1 Financial performance (Celgene Corporation)
8.1.6.3 Product benchmarking (Bristol-Myers Squibb)
8.1.6.3.1 Product benchmarking (Celgene)
8.1.6.4 Strategic Initiatives
8.1.6.4.1 Strategic Initiatives
8.1.7 SANOFI
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic Initiatives
8.1.8 APPLIED GENETIC TECHNOLOGIES CORPORATION
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic Initiatives
8.1.9 F. HOFFMANN-LA ROCHE LTD.
8.1.9.1 Company overview
8.1.9.1.1 Spark Therapeutics, Inc.
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic Initiatives
8.1.10 BLUEBIRD BIO, INC.
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic Initiatives
8.1.11 NOVARTIS AG
8.1.11.1 Company overview
8.1.11.1.1 AveXis, Inc.
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic Initiatives
8.1.11.4.1 Strategic Initiatives
8.1.12 TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. (GENE BIOTHERAPEUTICS)
8.1.12.1 Company overview
8.1.12.2 Product benchmarking
8.1.12.3 Strategic Initiatives
8.1.13 UNIQURE N.V.
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Product benchmarking
8.1.13.4 Strategic Initiatives
8.1.14 TAKEDA PHARMACEUTICAL COMPANY LIMITED
8.1.14.1 Company overview
8.1.14.2 Financial performance
8.1.14.3 Product benchmarking
8.1.14.4 Strategic Initiatives
8.1.15 CELLECTIS S.A.
8.1.15.1 Company overview
8.1.15.2 Financial performance
8.1.15.3 Product benchmarking
8.1.15.4 Strategic Initiatives
8.1.16 SANGAMO THERAPEUTICS, INC.
8.1.16.1 Company overview
8.1.16.2 Financial performance
8.1.16.3 Product benchmarking
8.1.16.4 Strategic Initiatives
8.1.17 ORCHARD THERAPEUTICS
8.1.17.1 Company overview
8.1.17.2 Financial performance
8.1.17.3 Product benchmarking
8.1.17.4 Strategic Initiatives
8.1.18 GILEAD LIFESCIENCES, INC.
8.1.18.1 Company overview
8.1.18.2 Financial Performance
8.1.18.3 Product benchmarking
8.1.18.4 Strategic Initiatives
8.1.19 BENITEC BIOPHARMA
8.1.19.1 Company overview
8.1.19.2 Financial Performance
8.1.19.3 Product benchmarking
8.1.19.4 Strategic Initiatives
8.1.20 SIBIONO GENETECH CO., LTD
8.1.20.1 Company overview
8.1.20.2 Product benchmarking
8.1.21 SHANGHAI SUNWAY BIOTECH CO., LTD.
8.1.21.1 Company overview
8.1.21.2 Product benchmarking
8.1.22 GENSIGHT BIOLOGICS S.A.
8.1.22.1 Company overview
8.1.22.2 Financial performance
8.1.22.3 Product benchmarking
8.1.22.4 Strategic initiatives
8.1.23 TRANSGENE
8.1.23.1 Company overview
8.1.23.2 Financial performance
8.1.23.3 Product benchmarking
8.1.23.4 Strategic initiatives
8.1.24 CALIMMUNE, INC.
8.1.24.1 Company overview
8.1.24.2 Product benchmarking
8.1.24.3 Strategic initiatives
8.1.25 EPEIUS BIOTECHNOLOGIES CORP.
8.1.25.1 Company overview
8.1.25.2 Product benchmarking
8.1.26 ASTELLAS PHARMA INC.
8.1.26.1 Company overview
8.1.26.2 Audentes Therapeutics, Inc.
8.1.26.2.1 Company overview
8.1.26.3 Financial performance
8.1.26.3.1 Financial performance
8.1.26.4 Product benchmarking
8.1.26.5 Strategic initiatives
8.1.27 AMERICAN GENE TECHNOLOGIES
8.1.27.1 Company overview
8.1.27.2 Product benchmarking
8.1.27.3 Strategic initiatives
8.1.28 BIOMARIN PHARMACEUTICALS, INC.
8.1.28.1 Company overview
8.1.28.2 Financial performance
8.1.28.3 Product benchmarking
8.1.28.4 Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Tables
Table 3 List of Secondary Sources
Table 4 List of Abbreviations
Table 5 Global Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 6 Global Gene Therapy Market by Region, 2018 - 2030 (USD Million)
Table 7 North America Gene Therapy Market by Country, 2018 - 2030 (USD Million)
Table 8 North America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 9 U.S. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 10 Canada Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 11 Europe Gene Therapy Market by Country, 2018 - 2030 (USD Million)
Table 12 Europe Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 13 Germany Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 14 UK Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 15 France Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 16 Italy Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 17 Spain Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 18 Asia Pacific Gene Therapy Market by Country, 2018 - 2030 (USD Million)
Table 19 Asia Pacific Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 20 China Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 21 Japan Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 22 India Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 23 Australia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 24 Rest Of The World Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

List of Figures

FIG. 1 Information Procurement
FIG. 2 Primary Research Pattern
FIG. 3 Market Research Approaches
FIG. 4 Value Chain-Based Sizing & Forecasting
FIG. 5 Market Formulation & Validation
FIG. 6 Gene Therapy Market Segmentation
FIG. 7 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 8 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 9 Market Challenge Relevance Analysis (Current & Future Impact)
FIG. 10 Penetration & Growth Prospect Mapping
FIG. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
FIG. 12 Porter’s Five Forces Analysis
FIG. 13 Market Penetration Vs Growth Prospect Mapping, 2022
FIG. 14 Number of gene therapy doses sold in 2022
FIG. 15 Patients treated with gene therapy in 2022
FIG. 16 Regional Marketplace: Key Takeaways
FIG. 17 Global Gene Therapy Market for Lentivirus 2018 - 2030 (USD Million)
FIG. 18 Global Gene Therapy Market for AAV 2018 - 2030 (USD Million)
图19全球逆转录病毒基因治疗市场& gamma RetroVirus 2018 - 2030 (USD Million)
FIG. 20 Global Gene Therapy Market for Modified Herpes Simplex Virus 2018 - 2030 (USD Million)
FIG. 21 Global Gene Therapy Market for Adenovirus 2018 - 2030 (USD Million)
FIG. 22 Global Gene Therapy Market for Non-viral Plasmid Vector 2018 - 2030 (USD Million)
FIG. 23 Global Gene Therapy Market for Other Vector Type 2018 - 2030 (USD Million)
FIG. 24 Global Gene Therapy Market for Acute Lymphoblastic Leukemia (ALL) 2018 - 2030 (USD Million)
FIG. 25 Global Gene Therapy Market for Inherited Retinal Disease 2018 - 2030 (USD Million)
FIG. 26 Global Gene Therapy Market for Large B-cell Lymphoma 2018 - 2030 (USD Million)
FIG. 27 Global Gene Therapy Market for ADA-SCID 2018 - 2030 (USD Million)
FIG. 28 Global Gene Therapy Market for Melanoma (lesions) 2018 - 2030 (USD Million)
FIG. 29 Global Gene Therapy Market for Beta-Thalassemia Major/SCD 2018 - 2030 (USD Million)
FIG. 30 Global Gene Therapy Market for Head & Neck Squamous Cell Carcinoma 2018 - 2030 (USD Million)
FIG. 31 Global Gene Therapy Market for Peripheral arterial disease 2018 - 2030 (USD Million)
FIG. 32 Global Gene Therapy Market for Spinal Muscular Atrophy (SMA), 2018 - 2030 (USD Million)
FIG. 33 Global Gene Therapy Market for Others 2018 - 2030 (USD Million)
FIG. 34 Regional Outlook, 2022 & 2030
FIG. 35 North America Gene Therapy Market 2018 - 2030 (USD Million)
图36美国基因治疗市场2018 - 2030美元Million)
FIG. 37 Canada Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 38 Europe Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 39 Germany Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 40 UK Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 41 France Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 42 Italy Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 43 Spain Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 44 Asia Pacific Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 45 Japan Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 46 China Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 47 India Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 48 Australia Gene Therapy Market 2018 - 2030 (USD Million)
FIG. 49 Rest Of The World Gene Therapy Market 2018 - 2030 (USD Million)